EClinCloud Becomes Signant Health's Exclusive Strategic Partner in Greater China

To better support the global growth and expansion of Chinese pharmaceutical companies and the shift toward digital clinical trials, EClinCloud Technology Co., Ltd. ("EClinCloud") and Signant Health, a leading global evidence-generation company, have formed an exclusive strategic partnership to jointly promote Signant's SmartSignals eCOA software and services in Greater China. EClinCloud will serve as Signant's exclusive representative for business operations in Greater China, bringing leading clinical development services to sponsors and CROs seeking technology to improve data collection quality.

Headquartered in the United States with more than 1700 employees across three continents, Signant Health focuses on complex neurology and oncology and advances clinical development in neurology, oncology, and other therapeutic areas through a suite of clinical trial technology solutions, scientific services, and collaborations with scientific organizations worldwide.
Clinical trials in China are advancing rapidly, with rapid progress in digitalization. As a global leader in eCOA and endpoint assessment, Signant Health places a strong focus on the patient experience, simplifies every step patients go through in clinical trials, brings deep therapeutic expertise, and has earned the trust and collaboration of hundreds of sponsors and CROs (including all of the top 20 pharmaceutical companies). Signant Health noted that working with EClinCloud will provide Signant with strong local support in Greater China, marking a significant milestone.

EClinCloud's comprehensive, unified clinical research platform includes not only next-generation CTMS, eTMF, EDC, RTSM, and more, but also future-ready solutions such as eCOA. Combined with precision medical evaluation frameworks across therapeutic areas, the platform remains patient-centric and leverages patient engagement to provide greater convenience for patients.
Dr. Qin Long, CEO of EClinCloud, said: "EClinCloud's clinical commercial and clinical services teams bring an international perspective and the capability to deliver services in accordance with international standards. Through this partnership, EClinCloud will establish a leading position in eCOA, scale management, and rater training while enhancing the patient experience. By combining EClinCloud's proprietary products with Signant's scientific and clinical operations expertise, we will help domestic and international pharmaceutical companies and research institutions expand patient access, improve data quality, and bring life-changing therapies to the global community."
About EClinCloud
Guided by its mission of "bringing effective treatments to patients through technological innovation," EClinCloud is a healthcare and life-sciences technology company based in China and serving the world. Through its seamlessly integrated end-to-end unified platform (spanning scale management, linguistic validation, study design, eCOA, EDC, CTMS, eTMF, and more) and precision medical evaluation frameworks across therapeutic areas (oncology, neurology, cardiology, pulmonology, dermatology, and others), EClinCloud is building a globally leading, patient-centric unified clinical evidence support SaaS cloud platform, helping well-known domestic and international pharmaceutical companies and research institutions improve R&D efficiency, accelerate the market launch of drugs and medical devices, and benefit countless patients.
For more information, please visit: www.eclincloud.com


